For financial year 2027, HSBC is projecting Semaglutide sales of $280 million for Dr. Reddy’s, of which $224 million are expected from Canada, assuming a mid-single-digit to low-double-digit unit market share. In a best case scenario, that figure could nearly double to $500 million.
